Rubius Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Rubius Therapeutics

09/08/2021 14:11

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted loss of 56 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 49 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Rubius Therapeutics Inc's reported EPS for the quarter was a
loss of 56 cents​.
* The mean earnings estimate of analysts had risen by about 1.7%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Rubius Therapeutics Inc shares had fallen by 11.4% this
quarter and gained 185.0% so far this year.
* The company reported a quarterly loss of $50.18 million.
* Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $32.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 9 at 01:10 p.m.  ​All
figures in US dollars unless otherwise stated